Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...

The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with ...

Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting ...

"Usually, GBS patients recover swallowing function but ... it is still a difficult and prolonged recovery for patients. In this particular case, all other functions, including swallowing, have ...

GBS is a neuromuscular emergency affecting at ... more complete functional recovery versus placebo across multiple time points and clinical efficacy measures. Also Read: Mid-Cap Firm Annexon ...

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at ...

Five-year-olds can be goofy. That was my first thought several years ago when my son stumbled and fell to the ground.

Annexon (ANNX) presented data for its late-stage targeted therapy for GBS and showcased new disease education activities at the AAN Annual ...

GBS is a rare disorder but can be life-threatening ... shutting down complement for too long may be detrimental to nerve repair and recovery." Improvements were seen with the 30 mg/kg dose ...

To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...